[PDF][PDF] Influence of a single exercise session on natural killer cell cytotoxicity and tumor infiltration in preoperative esophageal carcinoma patients–a study protocol.
A Schenk, F Baumann, CT Baltin… - Oncology Research …, 2016 - fis.dshs-koeln.de
… targeted pharmacological inhibition of the mTOR network to … the two most common adult
brain tumor entities – meningiomas and … with mCRC, who have already received an Oxaliplatin …
brain tumor entities – meningiomas and … with mCRC, who have already received an Oxaliplatin …
[图书][B] Nanoparticle-Mediated Communication in the Pancreatic Tumor Microenvironment
SS Linton - 2017 - search.proquest.com
… Pharmacological inhibition of TS results in several … , irinotecan hydrochloride, and
oxaliplatin (FOLFIRINOX) was … serum chemistries (albumin for hepatic function and BUN for …
oxaliplatin (FOLFIRINOX) was … serum chemistries (albumin for hepatic function and BUN for …
32. Deutscher Krebskongress Krebsmedizin heute
A Eggert, U Keilholz - 2016 - karger.com
… targeted pharmacological inhibition of the mTOR network to … the two most common adult
brain tumor entities – meningiomas and … with mCRC, who have already received an Oxaliplatin …
brain tumor entities – meningiomas and … with mCRC, who have already received an Oxaliplatin …
[HTML][HTML] Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) …
P Pedrazzoli, N Silvestris, A Santoro, S Secondino… - Esmo Open, 2017 - Elsevier
… in the treatment of cancer to dialysed patients. Because of the impaired renal function, …
The recommended dose of oxaliplatin for patients on dialysis has not yet been established. …
The recommended dose of oxaliplatin for patients on dialysis has not yet been established. …
3. がん薬物療法における臨床薬効評価学(PK/PD)
今村知世 - 臨床薬理, 2016 - jstage.jst.go.jp
… Dose-escalating and pharmacologic study of oxaliplatin in … a National Cancer Institute Organ
Dysfunction Working Group … of liver dysfunction: phase Ⅰ NCI Organ Dysfunction Working …
Dysfunction Working Group … of liver dysfunction: phase Ⅰ NCI Organ Dysfunction Working …
Avaliação da necessidade do ajuste de dose de platinas conforme a função renal de pacientes oncológicos do sul do Brasil.
CMC Santos - 2019 - repositorio.unisc.br
… research was to evaluate the adjustment of doses of platines and taxanes based on renal …
hepatic function of cancer patients of a reference hospital in cancer treatment. The data …
hepatic function of cancer patients of a reference hospital in cancer treatment. The data …
[图书][B] Geriatrik Onkoloji
AM SEDEF, B AKAGÜNDÜZ - 2021 - books.google.com
… patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A
phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J …
phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J …
[图书][B] Antineoplastik İlaçlar
AM SEDEF, AK GÜNEŞ, E Tülay - 2022 - books.google.com
… potential in oncology: pharmacological activity and mecha… Cytotoxic anticancer agents and
renal impairment study: the … Radiation recall with oxaliplatin: report of a case and a review …
renal impairment study: the … Radiation recall with oxaliplatin: report of a case and a review …
[PDF][PDF] Therapeutic targeting of tumor cell plasticity in colorectal cancer
EM Schmidt - 2018 - edoc.ub.uni-muenchen.de
… As KRAS mutations are highly frequent in CRC and are associated with poor survival in
patients with advanced CRC 26,119,120, therapeutic regimens for KRAS mutated CRC are of …
patients with advanced CRC 26,119,120, therapeutic regimens for KRAS mutated CRC are of …